Evaluate the going concern status of LMN Pharmaceuticals, a biotechnology company, based on the following financial information for the fiscal year ending December 31, 2023:

Financial Data:

• Total assets: $200,000,000
• Total liabilities: $150,000,000
• Total equity: $50,000,000
• Net income for the year: $8,000,000
• Cash and cash equivalents: $20,000,000
• Accounts receivable: $30,000,000
• Inventory: $40,000,000
• Property, plant, and equipment: $100,000,000
• Long-term debt: $120,000,000
• Accounts payable: $45,000,000
• Accrued expenses: $10,000,000
• Revenue for the year: $250,000,000
• Cost of goods sold: $100,000,000
• Operating expenses: $60,000,000

Income tax expense: $12,000,000